New Strategy Proposed for HR+, HER2– Advanced Breast Cancer

In certain patients with HR+, HER2– advanced breast cancer, switching from an aromatase inhibitor to camizestrant while continuing with a CDK4/6 inhibitor, can extend the benefit of first-line therapy.